VMX-C001 for Urgent Surgery in Patients Taking FXa DOACs
This study is testing if VMX-C001 can help control bleeding during urgent surgery or procedures for people who are taking FXa Direct Oral Anticoagulants (DOACs), which are blood thinners. Researchers want to see if VMX-C001 works better than the usual care given to help blood clot. They will compare a fixed dose of VMX-C001 to standard treatments. The main goal is to see how many participants have "good" or "excellent" control of bleeding during their procedure, as judged by experts who don't know which treatment was given. You may be able to join if you are 18 or older, need urgent surgery with a high bleeding risk, and are currently taking a FXa DOAC. The study aims to enroll 800 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study comparing VMX-C001 to usual care. It plans to enroll 800 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint measures the effect of VMX-C001 on bleeding control from the start to the end of the procedure on Day 1.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
At a glance
Conditions
Where it's being run
37 sites across 25 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Effect of VMX-C001 versus usual pharmacological care on haemostasisFrom start to end of required procedure (Day 1).
Proportion of participants with good or excellent haemostatic efficacy during the required procedure.